A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Inclusion Criteria:

• Physician-diagnosed asthma requiring treatment with medium- to high-dose ICS-LABAfor at least 12 months prior to screening.

• Pre-BD FEV1 < 80% predicted according to central over read value at Visit 2.

• Documented historical post-BD reversibility of FEV1 ≥ 12% and ≥ 200 mL in FEV1.

• At least 2 documented asthma exacerbations (requiring treatment with systemic CS,hospitalization, or emergency department visit) within 12 months prior to screeningbut not within the past 4 weeks prior to screening

• ACQ-6 ≥ 1.5 at screening.

Exclusion Criteria:

• Maintenance use of asthma controllers other than ICS-LABA.

• Have undergone bronchial thermoplasty.

• Current smokers or participants with a smoking history of ≥ 10 pack-years andparticipants using vaping products, including electronic cigarettes.

• Women who are pregnant (or who are considering pregnancy) or breastfeeding.

• Current conditions or history of other diseases, as follows:

• Clinically important pulmonary disease other than asthma ,Thrombocytopenia,coagulopathy, or platelet dysfunction.

• Venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, moderateto severe heart failure (NYHA Class III or IV), cerebrovascular accident, myocardialinfarction, coronary stenting, or CABG surgery.

• Diagnosis of other significant cardiovascular diseases, including but not limited toangina, peripheral arterial disease, or uncontrolled arrhythmias such as atrialfibrillation, supraventricular tachycardia, ventricular tachycardia, and forms ofcarditis.

• Recipient of an organ transplant that requires continued immunosuppression.

• Immunocompromised (eg, lymphoma, acquired immunodeficiency syndrome, Wiskott-Aldrichsyndrome).

• Any malignancies or history of malignancies.

• Chronic or recurrent infectious disease.

• Receipt of any biologic drugs used for asthma < 12 weeks or 5 half-lives (if known),whichever is longer, prior to screening